A simple scoring system from Rutgers Health experts and others predicts outcomes of minimally invasive procedures, potentially expanding treatment options.
Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an engineered immune cell therapy can halt the progression of the autoimmune disease.